FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure – Yahoo Finance

– RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide, VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol.” data-reactid=”13″ type=”text”>– RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide, VIP), which has been granted FDA Swiftly Music Designation, FDA emergency use IND authorization, and an expanded get entry to protocol.

RADNOR, Pa. and GENEVA, Aug. 6, 2020 /PRNewswire/ — NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) “Relief” today announced that NeuroRx has been granted Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure.” data-reactid=”14″ type=”text”>RADNOR, Pa. and GENEVA, Aug. 6, 2020 /PRNewswire/ — NeuroRx, Inc. and Support Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) “Support” on the modern time presented that NeuroRx has been granted Investigational Unique Drug (IND) permission to take a look at RLF-100 (aviptadil) for inhaled use in patients with reasonable and extreme COVID-19 in scream to stop progression to respiratory failure.

https://clinicaltrials.gov/ct2/show/NCT04360096.  The first phase will commence with patients hospitalized for severe COVID-19 who do not yet have respiratory failure.  If promising results are seen in the inpatient setting, the trial will expand to patients at home with mild and moderate COVID-19 in order to prevent the need for hospital admission.” data-reactid=”19″ type=”text”>The ogle is posted at https://clinicaltrials.gov/ct2/payment/NCT04360096.  The first fragment will initiate with patients hospitalized for extreme COVID-19 who possess now not but fetch respiratory failure.  If promising results are viewed in the inpatient atmosphere, the trial will accomplish higher to patients at home with light and reasonable COVID-19 in scream to stop the necessity for clinical institution admission.

Jonathan Javitt, MD, MPH, CEO of NeuroRx said, “Now that we know VIP suppresses replication of the SARS-CoV-2 virus in human lung cells, based on the outstanding work of the Oswaldo Cruz Institute (Rio de Janeiro).¹ We are optimistic that treatment with VIP will not only help patients on ventilators, but will help to stop the advancement of the virus in patients with earlier stages of COVID-19.  By blocking cytokine synthesis in the lung cells and increasing the production of surfactant, which is key to the lung’s ability to transmit oxygen, we are hopeful that inhaled VIP will prove to be of clinical benefit across a wider array of patients suffering respiratory complications from COVID-19 infection.” ” data-reactid=”20″ type=”text”>Professor Jonathan Javitt, MD, MPH, CEO of NeuroRx stated, “Now that we all know VIP suppresses replication of the SARS-CoV-2 virus in human lung cells, per the prominent work of the Oswaldo Cruz Institute (Rio de Janeiro).¹ We’re optimistic that therapy with VIP is now not going to simplest wait on patients on ventilators, nevertheless will wait on to cease the style of the virus in patients with earlier phases of COVID-19.  By blocking cytokine synthesis in the lung cells and lengthening the manufacturing of surfactant, which is key to the lung’s skill to transmit oxygen, we’re hopeful that inhaled VIP will payment to be of scientific relieve sooner or later of a grand wider array of patients suffering respiratory complications from COVID-19 an infection.” 

September 1, 2020.” data-reactid=”21″ type=”text”>The scientific trial of the inhaled formulation of RLF-100 is anticipated to initiate on or earlier than September 1, 2020.

Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the Alveolar Type II cell, which is critical for the transmission of oxygen to the body.  VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.” data-reactid=”23″ type=”text”>Vasoactive Intestinal Polypeptide (VIP) used to be first came sooner or later of by the unhurried Dr. Sami Acknowledged in 1970. Although first identified in the intestinal tract, VIP is now identified to be produced throughout the body and to be essentially concentrated in the lungs. VIP has been shown in extra than 100 explore-reviewed stories to fetch potent anti-inflammatory/anti-cytokine job in animal units of respiratory wound, acute lung misfortune, and irritation. Most importantly, 70% of the VIP in the body is certain to a uncommon cell in the lung, the Alveolar Sort II cell, which is serious for the transmission of oxygen to the body.  VIP has a 20-twelve months history of protected use in humans in a pair of human trials for sarcoidosis, pulmonary fibrosis, bronchial asthma/hypersensitive reaction, and pulmonary hypertension.

COVID-19-associated demise is essentially brought on by respiratory failure. Earlier than this acute fragment, nevertheless, there may be evidence of early viral an infection of the alveolar kind 2 cells. These cells are identified to fetch angiotensin changing enzyme 2 (ACE2) receptors at high ranges, which relieve as the route of entry for the SARS-CoV-2 into the cells. Coronaviruses are shown to replicate in alveolar kind 2 cells, nevertheless now not in the extra a style of kind 1 cells. These identical kind 2 alveolar cells fetch high concentrations of VIP receptors on their cell surfaces giving upward thrust to the hypothesis that VIP may seemingly particularly provide protection to these cells from misfortune.

Damage to the kind 2 alveolar cells is an an increasing selection of plausible mechanism of COVID-19 disease progression (Mason 2020). These if truth be told expert cells fetch up the extra accepted kind 1 cells that line the lungs. Extra importantly, kind 2 cells possess surfactant that coats the lung and is a must fetch for oxygen swap. Rather than RLF-100, no currently proposed treatments for COVID-19 particularly target these vulnerable kind 2 cells.

RLF-100 (aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said’s original work and was originally approved for human trials by the FDA in 2001 and the European Medicines Agency in 2005. VIP is known to be highly concentrated in the lungs and to inhibit a variety of inflammatory cytokines. Relief’s predecessor company, Mondo Biotech, was awarded Orphan Drug Designation in 2001 by the U.S. FDA for aviptadil in the treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. Mondo was awarded Orphan Drug Designation by the European Medicines Agency in 2006 for the treatment of acute lung injury and in 2007 for the treatment of sarcoidosis. Both Mondo and Relief have worked on development of an inhaled formulation of aviptadil for several years. Both the U.S. FDA and the EMEA have granted Investigational New Drug licenses for human trials of aviptadil.” data-reactid=”27″ type=”text”>RLF-100 (aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that used to be developed per Dr. Acknowledged’s accepted work and used to be in the initiate popular for human trials by the FDA in 2001 and the European Medicines Agency in 2005. VIP is identified to be extremely concentrated in the lungs and to inhibit a fluctuate of inflammatory cytokines. Support’s predecessor company, Mondo Biotech, used to be awarded Orphan Drug Designation in 2001 by the U.S. FDA for aviptadil in the therapy of Acute Respiratory Injure Syndrome and in 2005 for therapy of Pulmonary Arterial Hypertension. Mondo used to be awarded Orphan Drug Designation by the European Medicines Agency in 2006 for the therapy of acute lung misfortune and in 2007 for the therapy of sarcoidosis. Each and every Mondo and Support fetch labored on style of an inhaled formulation of aviptadil for several years. Each and every the U.S. FDA and the EMEA fetch granted Investigational Unique Drug licenses for human trials of aviptadil.